`Case 1:14—cv—O1453—LPS Document 97 Filed 04/01/16 Page 1 of 1 Page|D #: 2081
`
`PROCTOR l*iEYM/*\l\l ENERJO LLP
`
`PRACTICING THE ART OF LAW
`
`300 DELAWAREAVENUE - SUITE 200 - WILMINGTON, DELAWAREl980'l
`TEL:302.472.73OO - FAx:3O2.472.732O -
`\NVVW.PROCTOF2HE‘{MAN.COM
`
`Direct Dial: (302) 472-7311
`E-mail: dgattuso@p_roctorhcvman.com_
`
`April 1,2016
`
`VIA CMIECF and HAND DELIVERY
`
`The Honorable Leonard P. Stark
`
`J. Caleb Boggs Federal Building
`844 N. King Street
`Unit 26
`
`Wilmington, DE 19801-3555
`
`Re: Meda Pharmaceuticals Inc., et al v. Apotex Inc. and Apotex Corp.,
`C.A. No. 14-1453«LPS
`
`Dear Chief Judge Stark:
`
`I write as counsel to defendants Apotex, Inc. and Apotex Corp. (together, “ApoteX”) in the
`above-referenced action, regarding the Court’s Oral Order, dated January 22, 2016. (D.l. 82.) As
`indicated by the parties’ Joint Claim Construction Chart (D1. 95), Apotex does not seek to construe
`any additional terms in U.S. Patent No. 9,259,428. Accordingly, Apotex does not intend to file a.
`supplemental claim construction brief.
`In the event that Plaintiffs file a supplemental claim
`construction brief pursuant to D.I. 82, Apotex reserves the right to file a response to Plaintiffs’
`opening brief.
`
`Respectfully,
`
`/s/ Dominick T. Gattuso
`
`Dominick T. Gattuso (# 3630)
`
`DTG/jrt
`
`cc:
`
`Counsel of Record (via CM/ECF)